Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira

Yu,Jun; Drisko,Jeanne; Chen,Qi

doi:10.3892/or.2013.2461

Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira

Authors:
- Jun Yu
- Jeanne Drisko
- Qi Chen
View Affiliations

Affiliations: Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas city, KS 66160, USA, University of Kansas Integrative Medicine, University of Kansas Medical Center, Kansas city, KS 66160, USA
Published online on: May 14, 2013 https://doi.org/10.3892/or.2013.2461
Pages: 149-156

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lack of effective therapy is a major problem in the treatment of pancreatic cancer. In the present study, we investigated a natural product, the extract of Pao Pereira (Pao), for its anti-pancreatic cancer effect in vitro and in vivo, either alone or in combination with the first-line chemotherapeutic drug gemcitabine (Gem). Pao induced dose-dependent apoptosis to all five tested pancreatic cancer cell lines. The combination of Pao and Gem had a synergistic effect in the inhibition of cell growth, with combination indices (CIs) <1 by Chou-Talalay's median effect analysis based on the isobologram principle. Adding Pao to Gem treatment reduced the concentration of Gem to produce an equitoxic effect on pancreatic cancer cells. In an orthotopic pancreatic xenograft mouse model, mice bearing PACN-1 tumors were treated with Pao and Gem, either alone or in combination. The progression of tumors was monitored longitudinally by imaging of live animals. While Gem did not provide significant inhibition, Pao treatment significantly suppressed tumor growth by 70-72%. Combined Pao and Gem treatment further enhanced the tumor inhibitory effect compared to Gem alone, and markedly reduced metastatic lesions in the peritoneum. Collectively, these data suggest that the extract of Pao possesses anti-pancreatic cancer activity and can enhance the effects of Gem in vitro and in vivo.

View Figures

View References

1	Lowenfels AB and Maisonneuve P: Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol. 34:238–244. 2004. View Article : Google Scholar
2	Bayraktar S and Rocha-Lima CM: Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med. 77:606–619. 2010. View Article : Google Scholar : PubMed/NCBI
3	ACS. Cancer Facts and Figures. 2012, Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. (Accessed Jan 18, 2012)
4	Freelove R and Walling AD: Pancreatic cancer: diagnosis and management. Am Fam Physician. 73:485–492. 2006.PubMed/NCBI
5	Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI
6	Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
7	Cartwright T, Richards D and Boehm K: Cancer of the pancreas: are we making progress? a review of studies in the US Oncology Research Network. Cancer Control. 15:308–313. 2008.PubMed/NCBI
8	Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:24031997.PubMed/NCBI
9	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C and Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bemis DL, Capodice JL, Desai M, Katz AE and Buttyan R: beta-carboline alkaloid-enriched extract from the amazonian rain forest tree pao pereira suppresses prostate cancer cells. J Soc Integr Oncol. 7:59–65. 2009.PubMed/NCBI
11	Beljanski M and Beljanski MS: Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs. Oncology. 43:198–203. 1986. View Article : Google Scholar : PubMed/NCBI
12	Cao R, Chen Q, Hou X, Chen H, Guan H, Ma Y, Peng W and Xu A: Synthesis, acute toxicities, and antitumor effects of novel 9-substituted beta-carboline derivatives. Bioorg Med Chem. 12:4613–4623. 2004. View Article : Google Scholar : PubMed/NCBI
13	Chen Q, Chao R, Chen H, Hou X, Yan H, Zhou S, Peng W and Xu A: Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. Int J Cancer. 114:675–682. 2005. View Article : Google Scholar : PubMed/NCBI
14	Puiseux F, Le Hir A, Goutarel R, Janot MM and Lemen J: On the alkaloids of ‘pao-pereira’, Geissospermum laeve (Vellozo) Baillon. Note III. Geissoschizoline, apogeissoschizine and geissospermine. Ann Pharm Fr. 17:626–633. 1959.(In French).
15	Cole SP: Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol. 17:259–263. 1986.PubMed/NCBI
16	Denizot F and Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 89:271–277. 1986. View Article : Google Scholar : PubMed/NCBI
17	Chou T and Talalay P: Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. New Avenues in Developmental Cancer Chemotherapy. 8. Harrap KR and Connors TA: Academic Press; New York, NY: pp. 37–64. 1987
18	Chou T, Rideout D, Chou J and Bertino J: Chemotherapeutic synergism, potentiation and antagonism. Encyclopedia of Human Biology. 2. Dulbecco R: Academic Press, Inc; San Diego, CA: pp. 371–379. 1991
19	Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58:621–681. 2006. View Article : Google Scholar : PubMed/NCBI
20	Eagle H, Foley GE, Koprowski H, Lazarus H, Levine EM and Adams RA: Growth characteristics of virus-transformed cells. Maximum population density, inhibition by normal cells, serum requirement, growth in soft agar, and xenogeneic transplantability. J Exp Med. 131:863–879. 1970. View Article : Google Scholar
21	Zeng G, Cai S, Liu Y and Wu GJ: METCAM/MUC18 augments migration, invasion, and tumorigenicity of human breast cancer SK-BR-3 cells. Gene. 492:229–238. 2012. View Article : Google Scholar : PubMed/NCBI
22	Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B and Riess H: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar
23	Renouf D and Moore M: Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther. 10:529–540. 2010. View Article : Google Scholar : PubMed/NCBI
24	Rybak MJ: The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 42(Suppl 1): S35–S39. 2006. View Article : Google Scholar : PubMed/NCBI
25	Mertz W: The essential trace elements. Science. 213:1332–1338. 1981. View Article : Google Scholar : PubMed/NCBI
26	Nyberg F, Hou SM, Pershagen G and Lambert B: Dietary fruit and vegetables protect against somatic mutation in vivo, but low or high intake of carotenoids does not. Carcinogenesis. 24:689–696. 2003. View Article : Google Scholar : PubMed/NCBI
27	Donate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS and Mazar AP: Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res. 14:2137–2144. 2008. View Article : Google Scholar : PubMed/NCBI
28	Celik I, Surucu O, Dietz C, Heymach JV, Force J, Hoschele I, Becker CM, Folkman J and Kisker O: Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 65:11044–11050. 2005. View Article : Google Scholar : PubMed/NCBI
29	Nishi M, Ohba S, Hirata K and Miyake H: Dose-response relationship between coffee and the risk of pancreas cancer. Jpn J Clin Oncol. 26:42–48. 1996. View Article : Google Scholar : PubMed/NCBI